The shares of Dr Reddy’s Laboratories had been buying and selling at ₹1,231.50 down by ₹57.90 or 4.49 per cent on the NSE right this moment at 11 am.
Dr Reddy’s Laboratories reported a 2 per cent improve in internet revenue to ₹1,413 crore for the third quarter ended December 2024, with complete income rising 16 per cent to ₹8,358 crore.
The Hyderabad-based pharmaceutical firm attributed its development to the newly acquired Nicotine Alternative Remedy (NRT) enterprise, new product launches, and improved operational efficiencies. North American revenues grew marginally by 1 per cent to ₹3,380 crore, although experiencing a 9 per cent sequential decline as a consequence of worth erosion and decrease gross sales of sure merchandise like Lenalidomide.
- Additionally learn: Cyient shares hunch 19% submit management shifts and Q3 outcomes
European revenues surged 143 per cent, bolstered by the NRT enterprise, whereas rising markets noticed a 12 per cent improve, with Russia contributing a 19 per cent development. The Indian market expanded by 14 per cent.
Key highlights embody launching Toripalimab, an immuno-oncology drug for uncommon nasopharyngeal carcinoma, making India the third nation after the US and China to entry the remedy. The corporate additionally entered a voluntary licensing settlement with Gilead Sciences to fabricate an HIV remedy drug in over 120 nations.
Dr Reddy’s continues to concentrate on strengthening its generics and API enterprise whereas investing in strategic areas like client well being, digital therapeutics, and biosimilars. The corporate accomplished a US FDA inspection at its Hyderabad API facility, receiving a Kind 483 with seven observations, which had been promptly addressed.
The corporate additionally accomplished a share capital alteration by splitting present ₹5 shares into 5 ₹1 shares.
